A year ago, our family lost my mother to Progressive Supranuclear Palsy — PSP. It’s a disease most people have never heard of, even though it sits in the same broad family as Parkinson’s disease. I was her caregiver, and I watched her lose, piece by piece, the abilities we all take for granted. That experience is why pspmy.top exists: to gather information, and honestly, to hold on to hope for the families walking this same road right now.
Over the past couple of years, headlines about tiny “nanorobots” or “microrobots” — microscopic devices designed to travel through the bloodstream, cross the blood-brain barrier, and deliver treatment directly to damaged brain cells — have circulated widely in Parkinson’s disease research. It’s a fair question to ask: could this same technology one day reach PSP too?
The honest answer is: not yet, but the door is not closed. Here is what the science actually says, as of 2026.
PSP and Parkinson’s: Related, But Not the Same Disease
PSP is often mistaken for Parkinson’s because both cause stiffness, slow movement, and balance problems. But underneath, they are different diseases. Parkinson’s is mainly driven by a protein called alpha-synuclein. PSP, on the other hand, is a tauopathy — it is caused by clumps of a different protein, tau, which normally helps stabilize the internal skeleton of brain cells. In PSP, tau folds abnormally, sticks together into “tangles,” and the neurons around it weaken and die, especially in the brainstem and basal ganglia. This is the same tau protein involved in Alzheimer’s disease, which is part of why PSP research increasingly overlaps with Alzheimer’s research.
What Nanorobots Are Actually Being Tested For
Most current research on micro- and nanorobots for the brain is still preclinical — tested in cells and animals, not yet in people. Scientists are exploring magnetically guided microrobots, hydrogel-based carriers, and biologically inspired designs that can cross the blood-brain barrier and deliver drugs, neurotrophic factors, or even gene-editing tools directly to damaged tissue. This approach is being studied for brain tumors, Alzheimer’s disease, and Parkinson’s disease. It is a genuinely promising field — but it is also years away from being an approved treatment for any brain disease, PSP included.
The Good News: PSP Already Has Its Own Wave of Research
This is the part I wish someone had told me a year ago: PSP is not being ignored. Because it is a tauopathy, researchers are now going straight after the tau protein itself, using tools that in some ways are just as innovative as nanorobotics:
- NIO752 — an antisense oligonucleotide that reduces production of the tau gene (MAPT) — has advanced to Phase 3 trials.
- LM11A-31 — a small molecule that blocks a chemical modification of tau — is also moving into Phase 3.
- The PROSPER trial is testing FNP-223 to slow disease progression, measured on the PSP Rating Scale.
- UCSF is running the PSP Clinical Trial Platform (PTP), a master protocol testing multiple drug candidates at once, backed by a $75.4 million NIH grant — one of the largest ever awarded for this disease.
- New tau-PET imaging tracers, like PI-2620, are making it possible to see tau buildup in a living brain, which could finally allow earlier diagnosis instead of confirmation only after death.
Not every trial succeeds — an earlier tau antibody, gosuranemab, did not meet its goals in PSP, and that is worth saying honestly. But that is how research moves forward: each result, positive or negative, sharpens the next attempt.
Why PSP Deserves the Same Attention as Parkinson’s
PSP affects roughly 6 to 10 people per 100,000 — about 30,000 people in the United States, compared to roughly a million living with Parkinson’s. Rare diseases like PSP have historically received a fraction of the funding and public attention, even though they progress faster and, in my family’s experience, are just as devastating for patients and caregivers. Technologies like nanorobotics are being built around the diseases that get the most attention and funding first. PSP families deserve to see that same investment directed at tau-based diseases too, not years behind.
What You Can Do
- Follow reliable sources like CurePSP (psp.org), the leading nonprofit dedicated to PSP research and family support.
- Ask your neurologist about ongoing clinical trials — organizations like CurePSP and clinicaltrials.gov list current studies you or a loved one may be eligible for.
- Share accurate information about PSP. Misdiagnosis is common, and awareness genuinely speeds up diagnosis for other families.
- If you are able, consider supporting PSP-specific research funding — rare disease research depends heavily on public and philanthropic support.
This post is written in memory of my mother, and for every family currently caring for someone with PSP. You are not alone, and the research world has not forgotten you.
This article is for informational purposes only and does not constitute medical advice. Please consult a neurologist or movement disorder specialist for guidance specific to you or your loved one.
